查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1461374

全球肌紅蛋白市場：現況分析與預測（2023-2030）

Myoglobin Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於診斷測試的增加，全球肌紅蛋白市場規模預計將穩定成長在 4.32% 左右。 例如，2023年6月，Shineco, Inc.的控股子公司Changzhou Biowin Pharmaceutical Co., Ltd.獲得國家藥品監督管理局江蘇局批准開展三種主要心臟標誌物和一種心臟標誌物的聯合檢測。心臟5 分鐘測試已獲得行銷和分銷批准，該測試只需一次測試即可檢測心肌肌鈣蛋白I、肌紅蛋白和心臟脂肪酸結合蛋白，用於急性心肌梗塞的臨床診斷。 在預測期內，有幾個因素正在推動市場成長，例如心血管疾病和肌炎的增加，以及醫療保健領域投資的增加。 除此之外，肌紅蛋白診斷效率的提升帶來了有效的治療程序，這也穩定地推動了肌紅蛋白市場的發展。

依產品類型，市場分為人類肌紅蛋白、動物肌紅蛋白等。 由於包括心肌梗塞在內的心血管疾病病例不斷增加，獸用肌紅蛋白細分市場將在 2022 年佔據市場主導地位。 獸醫肌紅蛋白在科學研究中得到了廣泛的研究，特別是在生物化學、食品科學和營養學等領域。 研究人員正在研究肌紅蛋白的各個方面，包括其結構、功能和特性，以便更好地瞭解其在人體中的作用。 因此，在產品類型中，動物肌紅蛋白細分市場在 2022 年佔據了重要的市場佔有率。

根據應用，市場分為診斷和治療。 由於臨床試驗數量不斷增加，預計治療領域在預測期內將以高複合年增長率成長。 例如，2023 年 4 月，CytoSorbents, Inc. 評估了使用 CytoSorb 作為需要腎臟替代治療的橫紋肌溶解症患者標準護理的輔助手段進行體外治療肌紅蛋白的可行性。 製藥公司和學術機構正在投資研發，以開發針對淋巴球性視網膜病變的新型治療策略。 治療領域的成長是由技術創新、盛行率不斷提高、醫療保健服務的改善以及對早期介入和聯合治療方法的日益重視所推動的。 因此，從應用來看，治療領域預計在預測期內將表現出更高的複合年增長率。

根據最終用戶，市場分為醫院、診所和其他。 由於全球因心血管疾病住院的人數不斷增加，醫院細分市場佔據了市場主導地位。 這是因為醫院中配備了大多數診斷設備，因此醫院的診斷測試正在增加。 除此之外，醫院數量的增加也推動了該領域的成長。 例如，根據美國醫院協會的數據，截至 2022 年 10 月，美國約有 6,093 家醫院，其中包括由非營利組織以及州和地方政府營運的社區醫院。 因此，2022年醫院在肌紅蛋白市場中佔有很大佔有率。

為了更瞭解肌紅蛋白的市場介紹，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太地區其他地區）和世界其他地區。 預計在預測期內，亞太地區全球肌紅蛋白市場將以高複合年增長率成長。 預測期內臨床試驗數量的快速增加、可近性的提高以及醫療保健成本的多樣化等因素正在推動市場成長。 此外，心血管疾病的增加也對市場成長產生正面影響。 例如，過去幾十年來，印度冠心病的盛行率在農村地區為1.6%至7.4%，在城市地區為1%至13.2%。 該地區是主要心血管疾病宣傳項目和產品發佈的地點。 因此，預計亞太地區在預測期內將呈現更高的複合年增長率。

市場的主要營運公司包括 Merck KGaA、Abbott、F. Hoffmann-La Roche Ltd、Siemens Healthcare Private Limited、Thermo Fisher Scientific Inc.、OriGene Technologies, Inc.、Innovative Research、Worthington Biochemical Corporation 和 Hyasen Biotechnology公司。

目錄

第一章市場介紹

  • 市場定義
  • 主要目標
  • 利害關係人
  • 限制

第二章研究方法/先決條件

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對肌紅蛋白市場的影響

第 6 章肌紅蛋白市場收入，2020-2030

第 7 章市場分析：依產品類型

  • 人類肌紅蛋白
  • 動物用肌紅蛋白
  • 其他

第 8 章市場分析：依應用

  • 診斷
  • 處理中

第 9 章市場分析：依最終使用者劃分

  • 醫院
  • 診斷實驗室
  • 其他

第 10 章市場分析：依地區

  • 北美
    • 美國
    • 加拿大
    • 北美其他地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 其他領域

第 11 章肌紅蛋白市場動態

  • 市場驅動因素
  • 市場問題
  • 影響分析

第 12 章肌紅蛋白市場機會

第十三章肌紅蛋白市場趨勢

第 14 章需求/供給分析

  • 需求方分析
  • 供給面分析

第 15 章價值鏈分析

第16章比賽場景

  • 競爭狀況
    • 波特五力分析

第十七章公司簡介

  • Merck KGaA
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
  • OriGene Technologies, Inc.
  • Innovative Research
  • Worthington Biochemical Corporation
  • Hyasen Biotechnology Co., Ltd.
  • RayBiotech, Inc.

第十八章免責聲明

簡介目錄
Product Code: UMHE212679

Myoglobin is a protein found in muscle tissues that binds oxygen, storing it for use during muscle activity. It gives meat its red color and plays a crucial role in oxygen transport and storage within muscle cells. Myoglobin levels in the blood serve as a biomarker for certain medical conditions, particularly those affecting muscle tissue. Elevated levels of myoglobin indicate muscle damage or disease, such as rhabdomyolysis, myocardial infarction, or muscular dystrophy. Innovations in assay development and a rising number of clinical trials are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the myoglobin market globally.

The Myoglobin Market is expected to grow at a steady rate of around 4.32% owing to the rising number of diagnostic test launches in the market. For instance, in June 2023, Changzhou Biowin Pharmaceutical Co., Ltd., a majority-owned subsidiary of Shineco, Inc. received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of the National Medical Products Administration, which is a combination test of three major cardiac markers and can detect cardiac troponin I, myoglobin, and heart fatty acid binding protein for the clinical diagnosis of acute myocardial infarction in one test. Several factors, including rising cardiovascular disorders and myositis, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated diagnosis efficiency using myoglobin has resulted in effective treatment procedures which are also driving this market of myoglobin at a steady rate.

Based on the product type, the market is segmented into human myoglobin, animal myoglobin, and others. The animal myoglobin segment dominated the market in the year 2022 owing to the rising cases of cardiovascular diseases including myocardial infarction. Animal myoglobin is extensively studied in scientific research, particularly in fields such as biochemistry, food science, and nutrition. Researchers investigate various aspects of myoglobin, including its structure, function, and properties, to better understand its role in the human body. Thus, among the product types, the animal myoglobin segment held a significant market share in 2022.

Based on the application, the market is bifurcated into diagnosis and treatment. The treatment segment is expected to grow with a high CAGR during the forecast period because of the rising number of clinical trials. For instance, In April 2023, CytoSorbents, Inc. initiated a clinical trial to assess the feasibility of the extracorporeal therapy for the removal of myoglobin using the CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring renal replacement therapy. Pharmaceutical companies and academic institutions are investing in research and development to develop novel treatment strategies for lymphatic retinopathy. The growth of the treatment segment is driven by technological innovation, increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Thus, the treatment segment among applications is expected to witness a higher CAGR during the forecast period.

Based on end user, the market is categorized into hospitals, clinics, and others. The hospital segment is dominating the market owing to the rising hospital admissions for cardiovascular diseases globally. This is due to higher diagnostic tests in hospitals as most diagnostic equipment is available in hospital settings. Apart from this, the growing number of hospitals is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Thus, hospitals held a significant share of the myoglobin market in 2022.

For a better understanding of the market adoption of myoglobin, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global myoglobin market in the forecast period. Several factors such as a surge in the number of clinical trials being performed, enhanced accessibility, and diversified healthcare costs are driving the market's growth during the forecast period. Further, the increase in incidences of cardiovascular disorders is also having a positive impact on the market's growth. For instance, coronary heart disease prevalence rates in India have ranged from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations in the past several decades. There have been major awareness programs regarding cardiovascular diseases and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Some of the major players operating in the market include Merck KGaA; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthcare Private Limited; Thermo Fisher Scientific Inc.; OriGene Technologies, Inc.; Innovative Research; Worthington Biochemical Corporation; Hyasen Biotechnology Co., Ltd.; RayBiotech, Inc.

TABLE OF CONTENTS

1MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Myoglobin Market
  • 2.2.Research Methodology of the Myoglobin Market
  • 2.3.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE MYOGLOBIN MARKET

6MYOGLOBIN MARKET REVENUE (USD BN), 2020-2030F

7MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1.Human Myoglobin
  • 7.2.Animal Myoglobin
  • 7.3.Others

8MARKET INSIGHTS BY APPLICATION

  • 8.1.Diagnosis
  • 8.2.Treatment

9MARKET INSIGHTS BY END USER

  • 9.1.Hospitals
  • 9.2.Diagnostic Laboratories
  • 9.3.Others

10MARKET INSIGHTS BY REGION

  • 10.1.North America
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2.Europe
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3.Asia-Pacific
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4.Rest of World

11MYOGLOBIN MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12MYOGLOBIN MARKET OPPORTUNITIES

13MYOGLOBIN MARKET TRENDS

14DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15VALUE CHAIN ANALYSIS

16COMPETITIVE SCENARIO

  • 16.1.Competitive Landscape
    • 16.1.1.Porters Fiver Forces Analysis

17COMPANY PROFILED

  • 17.1.Merck KGaA
  • 17.2.Abbott
  • 17.3.F. Hoffmann-La Roche Ltd
  • 17.4.Siemens Healthcare Private Limited
  • 17.5.Thermo Fisher Scientific Inc.
  • 17.6.OriGene Technologies, Inc.
  • 17.7.Innovative Research
  • 17.8.Worthington Biochemical Corporation
  • 17.9.Hyasen Biotechnology Co., Ltd.
  • 17.10.RayBiotech, Inc.

18DISCLAIMER